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doi:10.1016/j.jtcvs.2004.02.006TObjectives: Perioperative myocardial damage is a major determinant of postopera-
tive cardiac dysfunction for congenital heart disease. Heart fatty acid–binding
protein is reported to be a rapid marker of perioperative myocardial damage that
peaks earlier than creatine kinase isoenzyme MB or cardiac troponin T in adults.
The objective of this study was to assess the suitability of using serum concentra-
tions of heart fatty acid–binding protein for evaluation of perioperative myocardial
damage in pediatric cardiac surgery.
Methods: After institutional review board approval and informed consent, 100
children undergoing open procedures for congenital heart disease were prospec-
tively enrolled in the study. Mean age at operation was 4.9  0.4 years. Serum
concentrations of heart fatty acid–binding protein, creatine kinase isoenzyme MB,
and cardiac troponin T were measured serially before operation and at 0, 1, 2, 3, and
6 hours after aortic declamping. Relationships between serum peak level of heart
fatty acid–binding protein and intraoperative and postoperative clinical variables
were evaluated.
Results: Serum heart fatty acid–binding protein reached its peak level at 1 hour after
declamping in 95 patients (95%), which was significantly earlier (P  .01) than
serum creatine kinase isoenzyme MB or cardiac troponin T. In addition, serum heart
fatty acid–binding protein level immediately after declamping correlated strongly
with serum peak heart fatty acid–binding protein level (r  0.91, P  .01). The
serum peak level of heart fatty acid–binding protein correlated with those of
creatine kinase isoenzyme MB (r 0.77, P .01) and cardiac troponin T (r 0.80,
P  .01). In the forward stepwise multiple regression analysis, age (P  .0001),
aortic crossclamp time (P  .0001), the presence of a ventriculotomy (P  .001),
and the lowest hematocrit level during cardiopulmonary bypass (P  .05) were
significant intraoperative variables that influenced the release of heart fatty acid–
binding protein. There were significant relationships between serum peak heart fatty
acid–binding protein level and postoperative inotropic support, duration of intuba-
tion, and intensive care unit stay (P  .01 for each).
Conclusions: Heart fatty acid–binding protein is a rapid marker for assessment of
myocardial damage and clinical outcome in pediatric cardiac surgery. In particular,
serum heart fatty acid–binding protein level immediately after aortic declamping
may be a potentially useful prognostic indicator of myocardial damage as well as
clinical outcome in pediatric cardiac surgery.
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DAlthough recent advances in surgical tech-nique and myocardial protection have ledto significant improvements in pediatriccardiac surgery, little has been reportedon assessment of myocardial damage byischemia and reperfusion in children.1,2 In
cardiac surgery, intraoperative myocardial damage is a ma-
jor determinant of postoperative cardiac dysfunction asso-
ciated with morbidity and mortality. Early and accurate
evaluation of myocardial damage would be clinically useful
for perioperative management. Currently, heart fatty acid–
binding protein (HFABP) has been introduced as a cardio-
specific marker for early evaluation of myocardial damage
in adult patients undergoing coronary artery bypass graft-
ing.3,4 We therefore measured plasma levels of HFABP
before and during the postoperative period in patients un-
dergoing open procedures for congenital heart disease with
two objectives: to assess the suitability of using serum
concentrations of HFABP for evaluation of intraoperative
myocardial damage in pediatric cardiac surgery and to clar-
ify whether HFABP can serve as an index to express intra-
operative myocardial damage as well as a prognostic indi-
cator for clinical outcome.
Methods
Patient Population
Two hundred twenty patients underwent elective open procedures
for congenital heart diseases between June 1999 and June 2000.
After approval was obtained from the institutional review board
and informed consent for all patients was obtained from their
parents, we selected 166 patients in this study. To establish a
baseline serum HFABP level in patients who underwent surgical
procedures, we applied the following exclusion criteria: previous
cardiothoracic procedure (n  54), preoperative inotropic support
(n  9), and postoperative complication resulting in surgical
reexploration within 6 hours after an aortic declamping (n  3).
Thus, 100 patients undergoing elective open procedures for con-
genital heart disease between June 1999 and June 2000 were
prospectively enrolled in the study protocol. Mean age at operation
was 4.9 0.4 years, ranging from 3 months to 17 years, and mean
body weight was 16.0  0.9 kg, ranging from 3.5 to 46.2 kg.
Diagnoses included ventricular septal defect (n  56), atrial septal
defect (n 15), tetralogy of Fallot (n 11), valvular disease (n
6), double-outlet right ventricle (n  5), complete atrioventricular
septal defect (n  4), and others (n  3).
Operative Procedure
Anesthesia was induced and maintained with fentanyl (50-100
g/kg) and vecuronium. Patients’ lungs were ventilated with ox-
ygen, air, and isoflurane, and ventilation was adjusted to maintain
normocarbia. Cardiopulmonary bypass (CPB) was instituted with
an ascending aortic cannula, bicaval venous cannulas, and a sys-
temic ventricular venting. A systemic flow was maintained be-
tween 2.2 and 2.6 L/(min · m2), and mean arterial pressure was
maintained between 40 and 60 mm Hg. Mild or moderate systemic
hypothermia was used. After completion of the surgical repair and
1698 The Journal of Thoracic and Cardiovascular Surgery ● Junaortic declamping, rewarming was instituted. CPB was discontin-
ued with minimal inotropic support, and modified ultrafiltration
was performed under stable hemodynamic conditions.
Protocol for Myocardial Protection
Myocardial protection was achieved with intermittent cold blood
cardioplegia with topical cardiac cooling in all patients. A dose of
300 mL/m2 body surface area was initially infused into the aortic
root at a pressure of 30 mm Hg to achieve cardiac arrest, with
subsequent doses of 150 mL/m2 body surface area infused every
20 minutes. In all patients an additional dose of 300 mL/m2 body
surface area warm (35°C) blood cardioplegic solution was infused
into the aortic root just before the aortic declamping.5 Blood
cardioplegic solution was made by mixing hyperkalemic crystal-
loid solution6 with oxygenated blood in the ratio of 1:2 and then
cooled to 9°C (Table 1). At the start of reperfusion, the aorta was
partially declamped for 3 minutes, and the aortic root pressure was
kept at less than 30 mm Hg to reduce reperfusion injury. The aorta
was then fully declamped. If ventricular fibrillation persisted be-
yond a few minutes after the aortic declamping, electrical defibril-
lation was applied to restore normal sinus rhythm.
Blood Samples and Biochemical Analysis
As markers of myocardial damage, serum concentrations of
HFABP, creatine kinase isoenzyme MB (CK-MB), and cardiac
troponin T (TnT) were measured at 6 points during the study
protocol as follows: after induction of anesthesia and before skin
incision and at 0, 1, 2, 3, and 6 hours after the aortic declamping.
All blood samples were collected through a radial arterial line and
centrifuged immediately. The plasma was frozen and stored until
biochemical analysis was performed. The serum HFABP level was
measured with a sandwich enzyme-linked immunosorbent assay
with two distinct murine anti-HFABP monoclonal antibodies
(Markit-M H-FABP; Dainippon Pharmaceutical Co Ltd, Osaka,
Japan).7 Activity of CK-MB was measured with an immunoinhibi-
tory assay, and the serum TnT level was quantified with an enzyme
immunoassay (SRL, Tokyo, Japan).
Assessment of Clinical Outcome
Relationship between serum peak level of HFABP and intraoper-
ative and postoperative clinical variables were evaluated. Intraop-
erative variables included diagnosis for surgery, durations of CPB
and aortic crossclamping, the lowest hematocrit and myocardial
TABLE 1. Composition and characteristics of blood cardio-
plegia
Sodium ion (mmol/L) 97.7 1.2
Potassium ion (mmol/L) 18.7 0.3
Chloride ion (mmol/L) 90.4 0.8
Magnesium ion (mmol/L) 1.0 0.01
Calcium ion (mmol/L) 0.73 0.01
pH 7.51 0.01
Bicarbonate ion (mmol/L) 17.4 0.3
Hematocrit (%) 18.6 0.6
Osmolarity (mOsm/L) 339 3.1
All data are shown as mean  SEM for each composition.temperature during CPB, the presence of a ventriculotomy, and the
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Drequirement of electrical defibrillation for heartbeat recovery after
aortic declamping. Postoperative variables included inotrope score
and durations of intubation and intensive care unit stay. Inotrope
score was defined as follows: the sum of the doses of dopamine
(g/[kg · min]), dobutamine (g/[kg · min]), and epinephrine
(g/[kg · min] 100) multiplied by the number of hours that each
drug was used.8
Statistical Analysis
All values are expressed as mean  SEM. Comparisons of the
times taken to reach serum peak levels among the 3 groups
(HFABP, CK-MB, and TnT) were performed with the Kruskal-
Wallis test. Simple linear regression analysis was performed by the
least squares method to determine the relationship of serum levels
in the 3 groups. The relationship between intraoperative variables
and serum peak levels in the 3 groups was analyzed with the
forward stepwise regression. Spearman rank correlation coeffi-
cients (2-tailed) were used to evaluate whether serum peak
HFABP level was correlated with postoperative clinical variables.
All statistical analyses were performed with the Statview (version
5.0) software package (SAS Institute, Inc, Cary, NC).
Results
Clinical Outcome
The intraoperative data are shown in Table 2. There were no
in-hospital deaths or major postoperative complications.
Transient electrocardiographic changes of minor ST-seg-
ment change were observed in 17 patients but were unre-
lated to the elevation of serum levels of biochemical mark-
ers. Inotropic support was required with dopamine (range
3-12 g/[kg · min]) in all cases, with dobutamine (range
2.5-10 g/[kg · min]) in 38 cases, and with epinephrine
(range 0.025-0.15 g/[kg · min]) in 9 cases. Inotrope score
was 561  89 (range 51-6648). Durations of intubation and
intensive care unit stay were 33  4.5 hours (range 3-283
TABLE 2. Intraoperative variables (n  100)
Age (mo, mean  SEM) 59 4 (3–209)
CPB time (min, mean  SEM) 146 6 (47–348)
Aortic crossclamping time (min,
mean  SEM)
77 4 (19–213)
Myocardial temperature during CPB
(°C, mean  SEM)
11.6 0.4 (3.0–24.0)
Lowest hematocrit during CPB (%,
mean  SEM)
17.1 0.3 (11.9–27.9)
Ventriculotomy (No.) 21
Electrical defibrillation (No.) 39
Diagnosis (No.)
Ventricular septal defect 56
Atrial septal defect 15
Tetralogy of Fallot 11
Valvular disease 6
Double-outlet right ventricle 5
Atrioventricular septal defect 4
Other 3hours) and 4.5  0.5 days (range 1-41 days), respectively.
The Journal of ThoracicSerial Changes in Biochemical Markers
Serial changes in HFABP, CK-MB, and TnT levels are
illustrated in Figure 1. The baseline serum HFABP level
before the operation ranged from 1.1 to 8.6 ng/mL (mean
4.3  0.2 ng/mL). Serum HFABP level rose sharply from
the baseline to the peak and reached the peak at 1 hour after
aortic declamping, then quickly normalized without double
peak formation. Serum peak HFABP level ranged from 48
to 1200 ng/mL (mean, 316  26 ng/mL). The baseline
serum CK-MB level before the operation ranged from 2.3 to
18.0 IU/L (mean 6.8  0.3 IU/L). Serum TnT before the
operation was not detectable in all patients. Serum CK-MB
reached the peak level at 2 hours after declamping and
gradually declined with a persistently high level. Serum
peak CK-MB level ranged from 78 to 1537 IU/L (mean 337
 24 IU/L). Serum TnT level also peaked at 2 hours after
declamping, ranging from 5 to 55 ng/mL (mean 27  1.3
ng/mL). Serum HFABP reached the peak level at 1 hour in
95 patients (95%) and within 2 hours after declamping in all
patients. In contrast, peak levels of serum CK-MB and TnT
were seen at a range of 1 to 6 hours after declamping. The
time taken to reach serum peak level was significantly less
for HFABP than for the other 2 groups (P  .01 by
Kruskal-Wallis test).
Correlations Between Serum Peak Levels of
Biochemical Markers
Serum peak HFABP level correlated significantly with se-
rum peak CK-MB level (r  0.766, P  .01; Figure 2, A)
and serum peak TnT level (r 0.796, P .01; Figure 2, B).
Serum HFABP level immediately after aortic declamping
correlated strongly with serum peak HFABP level (r 
Figure 1. Serum levels of HFABP (open circles), CK-MB (filled
squares), and TnT (filled triangles) during study protocol. Results
are expressed as mean  SEM (error bars). Asterisk indicates P
< .01; time to reach serum peak level was significantly earlier for
HFABP than for CK-MB and TnT.0.910, P  .01; Figure 3).
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In the forward stepwise multiple regression analysis, age (P
 .0001), aortic crossclamping time (P  .0001), the pres-
ence of a ventriculotomy (P  .001), and the lowest hemat-
ocrit during CPB (P  .05) were significant intraoperative
variables that influenced the release of HFABP (Table 3A).
Age, aortic crossclamping time, and the presence of a ven-
triculotomy were also significantly correlated with the re-
lease of CK-MB and TnT (P  .01 for each; Tables 3B and
3C).
Relationship of HFABP Level to Postoperative
Outcome Variables
Serum peak HFABP level correlated significantly with ino-
trope score, intubation time, and intensive care unit stay,
with Spearman rank correlation coefficients greater than
0.50 (P  .01 for each; Table 4). In particular, a good
correlation between serum peak HFABP level and inotrope
score was observed, with a correlation coefficient of 0.73
Figure 2. Correlations between serum peak HFABP level and
serum peak CK-MB (A) and TnT (B) levels.
Figure 3. Correlation between serum HFABP level immediately
after aortic declamping and serum peak HFABP level.(Figure 4).
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Important characteristics to determine the utility of a bio-
chemical marker for myocardial damage are its cellular
localization, aqueous solubility, clearance from blood cir-
culation, specificity for myocardium, and detectability in
plasma.9 Recently, HFABP has been introduced as a plasma
marker for early evaluation of myocardial damage3,4 and
estimation of infarct size10 in adult patients. HFABP is a
TABLE 3A. Forward stepwise regression analysis for peak
HFABP (ng/mL)
Variable Coefficient SE t Value P value
Constant 41.47 116.62
Age (mo) 2.49 0.41 6.07 .0001
Aortic crossclamping time (min) 2.92 0.51 5.76 .0001
Ventriculotomy (yes  1, no  0) 167.15 47.43 3.52 .0007
Lowest hematocrit level (%) 14.18 6.55 2.16 .0330
Adjusted R 2  0.54, analysis of variance for the full regression P  .001.
TABLE 3B. Forward stepwise regression analysis for peak
CK-MB (IU/L)
Variable Coefficient SE t Value P value
Constant 422.09 71.57
Age (mo) 1.60 0.38 4.17 .0001
Aortic crossclamping time (min) 1.45 0.49 2.93 .0042
Ventriculotomy (yes  1, no  0) 266.94 44.45 6.01 .0001
Myocardial temperature (°C) 13.73 4.20 3.27 .0015
Adjusted R 2  0.53, analysis of variance for the full regression P  .001.
TABLE 3C. Forward stepwise regression analysis for peak
TnT (ng/mL)
Variable Coefficient SE t Value P value
Constant 21.96 2.84
Age (mo) 0.11 0.02 4.52 .0001
Aortic crossclamping time (min) 0.12 0.03 4.12 .0001
Ventriculotomy (yes  1, no  0) 8.61 2.79 3.08 .0027
Adjusted R 2  0.40, analysis of variance for the full regression P  .001.
TABLE 4. Correlation between serum peak HFABP levels
and postoperative clinical variables
Variable Median
Interduatile
range r Value P value
Inotrope score* 228 152-522 0.799 .01
Intubation time (h) 16 8-26 0.598 .01
Intensive care unit stay (d) 2 2-6 0.600 .01
*Sum of doses of dopamine (g/[kg · min]), dobutamine (g/[kg · min]), and
epinephrine (g/[kg · min]  100) multiplied by number of hours each drug
was used.soluble cytoplasmic protein consisting of 132 amino acid
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Dresidues and weighing 14.9 kd, and it is abundant especially
in the cytoplasm of cardiomyocyte in free form. HFABP is
immunologically distinguishable from other types of fatty
acid–binding protein: liver, intestine, adipocyte, myelin,
brain, and so on. Its physiologic role is the transport of
long-chain fatty acids from the cell membrane to their
intracellular sites of metabolism in the mitochondria, where
they enter the citric acid cycle. Because this protein features
a low-molecular weight and a cytosolic localization, it leaks
out easily from the injured myocardium and immediately
enters the blood circulation.11-13
In our study the preoperative baseline serum HFABP
level in children was congruent with that reported previ-
ously for adults (mean 3.8  0.2 ng/mL, range 1.9-5.5
ng/mL).3 Judging from this result, we can say with fair
certainty that normal preoperative HFABP values in chil-
dren are in the same range as those in adults. On the other
hand, the serum peak HFABP level showed a greater ten-
dency to increase in children than adults. The serum peak
HFABP level in children without a ventriculotomy was 48
to 1200 ng/mL (mean 260  25.7 ng/mL) in our series, but
Suzuki and colleagues3 have reported that the level in adults
ranges from 64.9 to 139.0 ng/mL (mean 93.2 5.4 ng/mL).
Previously, Toyoda and associates5 implied that serum
HFABP reached to peak level at 1 hour after declamping in
pediatric cardiac surgery. In this study, serum HFABP level
formed a sharp peak at 1 hour after aortic declamping, and
95% of the patients reached their individual peak levels at
this time point. Suzuki and colleagues3 demonstrated that
HFABP peaked 47.3  2 minutes after the release of the
aortic crossclamp in a group of 20 patients with coronary
heart disease. Fransen and colleagues14 showed that periop-
erative myocardial damage could already be diagnosed from
the release of HFABP into plasma at 0.5 hours after reper-
fusion in 57 patients with various cardiac diagnoses and
operations. Serum HFABP reached the peak level signifi-
cantly earlier than did CK-MB and TnT. After reaching
peak level, serum HFABP decreased quickly in all patients,
whereas serum CK-MB and TnT levels remained at high
levels or showed double peaks in 12% or 14% of the
patients, respectively. These results suggest that HFABP is
expected to be a sensitive and specific marker for use in
early detection of myocardial damage. Serum peak HFABP
level also revealed a significant correlation with serum
HFABP level immediately after declamping. We believe
that serum HFABP level immediately after declamping can
predict serum peak HFABP level and rapidly detect myo-
cardial damage. Although it currently takes approximately 1
hour to measure serum HFABP level with the sandwich
enzyme immunoassay kit, we can get information about
myocardial damage earlier with HFABP than with CK-MB
or TnT.
The Journal of ThoracicWe found that myocardial damage with the release of
HFABP as well as CK-MB and TnT was dependent on age,
aortic crossclamping time, and the presence of ventriculot-
omy in the stepwise multiple regression model. Taggart and
associates1 have reported that age and ischemic time are
highly significant explanatory variables for the release of
CK-MB and TnT and that the presence of an atriotomy or
ventriculotomy is a significant explanatory variable for the
release of TnT. A negative correlation was found between
age and the release of HFABP. It seems that the younger
patients are, the more vulnerable their myocardia are to
injury during cardiac surgery. Trauma to the pediatric heart
during surgery, not only from direct surgical incisions such
as ventriculotomy but also from technical procedures such
as aortic crossclamping, causes myocardial cell damage and
the release of biochemical markers. In our study 69% of the
patients did not require any blood products during and after
surgery. On the other hand, our results showed that lowest
hematocrit during CPB correlated significantly with serum
peak level of HFABP. CPB with hemodilution is reported to
be associated with organ dysfunction as a result of tissue
edema and hypoxemia.15 Leung and associates16 have spec-
ulated that acute and severe isovolemic hemodilution pro-
duces an imbalance in myocardial oxygen supply and de-
mand, resulting in myocardial ischemia. We should take
great care to avoid excessive hemodilution in pediatric
cardiac surgery without blood transfusion.
This study suggests that the serum HFABP level after
aortic declamping may be a prognostic indicator for post-
operative clinical outcome. Higher elevations of serum
HFABP level required a larger amount of inotropic support
and a longer intubation time, with resultant prolongation of
intensive care unit stay. When we study these relationships
Figure 4. Correlation between serum peak HFABP level and ino-
trope score (sum of doses of dopamine [g/(kg · min)], dobut-
amine [g/(kg · min)], and epinephrine [g/(kg · min)  100]
multiplied by number of hours each drug was used).in larger numbers, it may be possible to determine a thresh-
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ative clinical course.
This study population was carefully selected to establish
a baseline serum HFABP level in pediatric patients under-
going cardiac surgery. Because of this selectivity, the lim-
itation of this study is that no neonatal patients and few
cyanotic patients were included in our series. Another pos-
sible limitation is that postoperative clinical variables can
differ according to the subjective judgment of the clinician
managing the patient. Clinician bias is, however, unlikely to
have been a confounding factor because the postoperative
management was strictly in accordance with our unit pro-
tocol, and the results were not available to the clinician.
In conclusion, serum HFABP reached the peak level
significantly earlier than serum CK-MB or TnT, and the
peak level of HFABP could be predicted from the level
immediately after aortic declamping. Our data indicate that
HFABP is a rapid indicator for the assessment of myocar-
dial damage and clinical outcome in pediatric cardiac sur-
gery. Prognostic information of HFABP makes it possible
for us to check on the quality of surgical technique and
myocardial protection and to start early treatment for myo-
cardial damage.
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